迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02493 迈威生物-B

未开盘 07-22 16:08:02

22.840

-0.360

-1.55%

最高24.280	最低22.800	成交量46.58万
今开22.840	昨收23.200	日振幅6.38%
总市值102.09亿	流通市值10.76亿	总股本4.47亿
成交额1,092万	换手率0.99%	流通股本4,713万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":22.84,"timestamp":1784707682077,"preClose":23.2,"halted":0,"volume":465800,"delay":0,"changeRate":-0.01551724137931032,"floatShares":47130200,"shares":447000000,"eps":-2.812394492103571,"marketStatus":"未开盘","change":-0.36,"latestTime":"07-22 16:08:02","open":22.84,"high":24.28,"low":22.8,"amount":10918140,"amplitude":0.063793,"askPrice":23.3,"askSize":600,"bidPrice":22.84,"bidSize":1800,"shortable":0,"etf":0,"ttmEps":-2.697815457240092,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":0,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":23.2,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":1.062403,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":33.69,"timestamp":1784703600000,"preClose":32.68,"halted":0,"volume":13203700,"delay":0,"premium":"-41.42"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2652296889","title":"7月20日迈威生物涨7.39%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652296889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652296889?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:24","pubTimestamp":1784535866,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日迈威生物涨7.39%，收盘报33.29元，换手率6.53%，成交量15.03万手，成交额4.92亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.8013，较上一交易日下跌7.07%，近一年下跌14.3%。易方达医药生物股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000024357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000808.SH","02493","163118","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237484","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获准开展白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237484","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652237484?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:35","pubTimestamp":1784396110,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，迈威生物报收于31.0元，较上周的31.87元下跌2.73%。本周，迈威生物7月16日盘中最高价报36.0元。此前，该药品用于炎症性肠病、多发性硬化和1型糖尿病适应症的临床试验申请已获国家药监局批准，其中IBD适应症还获得FDA许可。9MW5211为全球首个靶向该分子的临床阶段候选药物，临床前研究显示其在多种自身免疫疾病模型中具有显著治疗潜力，且安全性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145126713","title":"迈威生物-B：9MW5211注射液白癜风适应症临床试验获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1145126713","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145126713?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:13","pubTimestamp":1784117584,"startTime":"0","endTime":"0","summary":"2026年7月15日，迈威（上海）生物科技股份有限公司发布自愿性公告称，其自主研发的9MW5211注射液用于白癜风适应症的临床试验申请已获国家药品监督管理局批准。公告显示，9MW5211注射液境内生产药品注册临床试验申请编号为2026LP021512。该申请于2026年5月11日受理，经审评符合药品注册相关要求，同意开展白癜风临床试验。9MW5211是一种高度特异性的清除型创新抗体，靶向在致病性免疫细胞表面特异性表达的分子，以精确清除病理性免疫细胞、阻断免疫级联反应。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198929758","title":"迈威生物-B(02493)获批开展9MW5211白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198929758","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198929758?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:00","pubTimestamp":1784116834,"startTime":"0","endTime":"0","summary":"2026年7月16日，迈威（上海）生物科技股份有限公司公告，其自主研发的9MW5211注射液针对白癜风的临床试验申请获国家药品监督管理局核准签发《药物临床试验批准通知书》。根据审批结论，监管机构同意公司在境内开展9MW5211注射液用于白癜风适应症的临床试验。公告显示，9MW5211为公司自主研发的清除型创新抗体，靶向自身免疫疾病中由异常免疫细胞介导的关键病理机制。公司将按照规定及时披露项目进展信息，投资者需注意投资风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457887","title":"迈威生物：9MW5211注射液获国家药监局批准开展白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457887","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651457887?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:51","pubTimestamp":1784112680,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于白癜风适应症的临床试验申请获得批准。该药物是公司自主研发的清除型创新抗体，针对自身免疫性疾病中异常免疫细胞介导的关键病理机制进行精准干预。此前，该药物用于炎症性肠病、多发性硬化和1型糖尿病等适应症的临床试验申请已获批准。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500037751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651539944","title":"7月15日迈威生物涨7.67%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651539944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651539944?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:19","pubTimestamp":1784103544,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日迈威生物涨7.67%，收盘报35.38元，换手率8.17%，成交量18.8万手，成交额6.54亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.8276，较上一交易日上涨1.6%，近一年下跌3.97%。易方达医药生物股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","000808.SH","02493","163118"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650115423","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2650115423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650115423?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:49","pubTimestamp":1783795748,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，迈威生物报收于31.87元，较上周的32.06元下跌0.59%。本周关注点公司公告汇总：9MW5211注射液用于1型糖尿病适应症的临床试验申请获国家药监局批准公司公告汇总：该药品此前已获批用于炎症性肠病和多发性硬化适应症的临床试验公司公告汇总：9MW5211注射液针对多种自身免疫性疾病核心病理机制，具高度特异性公司公告汇总迈威生物自愿披露关于9MW5211注射液临床试验申请获得国家药品监督管理局批准的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996456","title":"活力中国调研行｜探访迈威生物：立足张江科创，直击临床刚需","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996456","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649996456?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:41","pubTimestamp":1783514463,"startTime":"0","endTime":"0","summary":"7月8日，记者跟随“2026年活力中国调研行”主题采访活动走进张江创新药企业迈威生物，实地探访企业从基础靶点发现、前沿技术开发到临床转化落地的全链条创新体系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798618939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159982","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100315193","title":"迈威生物-B（02493）9MW5211注射液获批开展1型糖尿病临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1100315193","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100315193?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:08","pubTimestamp":1783429712,"startTime":"0","endTime":"0","summary":"7月7日，迈威生物-B公告称，其自主研发的创新抗体药物9MW5211注射液针对1型糖尿病的临床试验申请获国家药品监督管理局批准，临床试验通知书编号为2026LP020092，受理日期为2026年4月27日。公司表示，9MW5211此前已获准在炎症性肠病及多发性硬化等适应症开展临床试验，其中IBD适应症已分别获得NMPA批准及美国食品药品监督管理局许可。迈威生物表示，将依据监管要求及时披露项目后续进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987609","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649987609?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:15","pubTimestamp":1783426507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于1型糖尿病适应症的临床试验申请获得批准，此前，其用于炎症性肠病适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可，用于多发性硬化适应症的临床试验申请已获得国家药品监督管理局批准。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","IBBQ","BK1161","BK0239","BMED","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188352203","title":"迈威生物-B 2026年6月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1188352203","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188352203?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:52","pubTimestamp":1783414328,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司于2026年7月7日发布了《股份变动月报表》，报告期为2026年6月。月报显示，公司在本月内未发生新的股份发行、回购或注销等变动，整体股本保持稳定。本月底公司法定注册股本合计达到人民币446,730,200元。两类股份在报告期内均无新增发行或减少情形，总股本维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649429256","title":"7月6日迈威生物涨5.68%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649429256","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649429256?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:30","pubTimestamp":1783326615,"startTime":"0","endTime":"0","summary":"证券之星消息，7月6日迈威生物涨5.68%，收盘报33.88元，换手率9.77%，成交量22.48万手，成交额7.75亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.8081，较上一交易日上涨3.66%，近一年下跌3.07%。易方达医药生物股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600022018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","000808.SH","163118","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648660223","title":"迈威生物获得发明专利授权：“一种全人源单克隆抗体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2648660223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648660223?lang=zh_cn&edition=full","pubTime":"2026-07-04 03:45","pubTimestamp":1783107944,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示迈威生物新获得一项发明专利授权，专利名为“一种全人源单克隆抗体及其应用”，专利申请号为CN202011138133.7，授权日为2026年7月3日。专利摘要：本公开提供一种全人源治疗性单克隆抗体或其片段，所述单克隆抗体是从Covid19患者康复期血液样本中分离单个B细胞克隆获得的特异性结合SARSCoV2S蛋白RBD区的全人源抗体，其对SARSCoV2感染THP1细胞和K562细胞均不产生ADE效应。今年以来迈威生物新获得专利授权9个，较去年同期增加了800%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070400003716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648963169","title":"迈威生物（688062）2607万股限售股将于7月3日解禁，占总股本5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648963169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648963169?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:02","pubTimestamp":1783036924,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迈威生物于7月3日将有2607.0万股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本5.84%。本次解禁后，公司还有1.69亿股限售股份，占总股本37.91%。本文数据来源于迈威生物公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300008547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688062","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648368855","title":"迈威生物：截至2026年一季度末，公司在手现金及现金等价物余额为14.83亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648368855","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648368855?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:00","pubTimestamp":1782997200,"startTime":"0","endTime":"0","summary":"证券日报网7月2日讯，迈威生物在接受调研者提问时表示，截至2026年一季度末，公司在手现金及现金等价物余额为14.83亿元。此外，2026年4月28日，公司在香港联合交易所主板正式挂牌上市，募资净额约11.89亿港元。2026年及未来，创新研发仍然是公司长远发展的价值保障与核心战略，公司将根据核心管线的推进情况合理规划研发费用的投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023792165687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648083515","title":"7月1日迈威生物涨9.73%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648083515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648083515?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:38","pubTimestamp":1782895102,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日迈威生物涨9.73%，收盘报31.0元，换手率8.87%，成交量18.1万手，成交额5.39亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.7407，较上一交易日下跌1.04%，近一年下跌6.38%。易方达医药生物股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","163118","BK1161","000808.SH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646648337","title":"迈威生物跌6.85% 2022年上市募34.77亿国泰海通保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2646648337","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646648337?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:03","pubTimestamp":1782460982,"startTime":"0","endTime":"0","summary":"中国经济网北京6月26日讯 迈威生物 今日收报25.82元，跌幅6.85%。　　迈威生物首次公开发行股票的发行费用合计1.85亿元，其中，保荐承销费1.55亿元。　　迈威生物披露的上市公告书显示，海通证券安排子公司海通创新证券投资有限公司参与本次发行战略配售，配售数量为本次公开发行数量的2.88%，即287.3563万股，获配金额9999.9992万元；海通创新证券投资有限公司本次跟投获配股票的限售期为24个月，限售期自本次公开发行的股票在上交所上市之日起开始计算。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260626/32291042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","02611","BK0184","BK1564","BK0201","BK1147","BK0028","BK1161","BK0188","BK0183","601211","BK0276","IPOS","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646646809","title":"迈威生物（688062）披露首次公开发行部分限售股上市流通公告，6月25日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646646809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646646809?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:27","pubTimestamp":1782397637,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，迈威生物报收于27.72元，较前一交易日上涨0.14%，最新总市值为123.83亿元。近日，迈威（上海）生物科技股份有限公司发布《首次公开发行部分限售股上市流通公告》。公告显示，公司首次公开发行部分限售股将于2026年7月3日上市流通，本次上市流通数量为26,070,000股，占公司A股股本的6.52%，占总股本的5.84%。上述股东已履行相关承诺，保荐机构对本次限售股上市流通无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645894983","title":"迈威生物：9MW5211注射液两项适应症临床试验获批 覆盖多发性硬化、炎症性肠病","url":"https://stock-news.laohu8.com/highlight/detail?id=2645894983","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645894983?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:15","pubTimestamp":1782296100,"startTime":"0","endTime":"0","summary":"6月24日，迈威生物（688062/02493）发布公告，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于多发性硬化（MS）适应症的临床试验申请获得批准。此外，9MW5211用于炎症性肠病（IBD）适应症的临床试验申请也已获得批准，且公司正在积极推进其他多个适应症的临床试验申请工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781539226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645880777","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645880777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645880777?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:37","pubTimestamp":1782211020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请获得批准。6MW5311是基于公司T Cell Engager(TCE)技术平台开发的一款靶向LILRB4/CD3的双特异性抗体，拟开发适应症为：血液瘤(AML、CMML以及MM)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":-0.0783},{"period":"1month","weight":-0.1348},{"period":"3month","weight":-0.1737},{"period":"ytd","weight":-0.1737}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}